Novo Nordisk Scores Hemophilia Win but Stumbles on Obesity Device as Buyback and India Launch Provid
Novo Nordisk’s stock has clawed back more than 40% from its March nadir, yet the Danish drugmaker’s latest…
Novo Nordisk’s Mixed Bag: Zenagamtide Data Delights, CagriSema Stumbles, Veru Deal Emerges
Novo Nordisk stock fell 4.4% on CagriSema’s weight loss gap vs Lilly; Zenagamtide slashed HbA1c 1.71% in Phase…